We are learning more about a stock sale by Pfizer CEO Albert Bourla on Monday, the same day the company announced its early vaccine trial results. We’ve seen certain circumstances like this before. That’s right… so remember, of course, Pfizer reported that 90 percent efficacy number on its vaccine trial on Monday. Its stock went up quite a bit. We’re now learning that Pfizer CEO Albert Bourla sold 5.6 million dollars worth of stock, 132,500 shares, on November 9th.
Pfizer CEO Sold $5.6 Million Stock in Pre-Planned Sale on Day of Vaccine News Release
Published November 17, 2020 | Best in Video